書誌事項
- タイトル別名
-
- A case of hepatocellular carcinoma treated sorafenib therapy showing interesting clinical course about treatment interruption
- ショウレイ ホウコク Sorafenib ノ トウヨ チュウシ ジキ ニ ツイテ キョウミブカイ リンショウ ケイカ オ シメシタ カン サイボウガン ノ 1レイ
この論文をさがす
抄録
A 87-years-old man with hepatocellular carcinoma (HCC) was treated with surgical resection at 85-years-old. Multiple recurrent HCC was treated with transcatheter arterial chemoembolization (TACE). Because TACE showed unsatisfactory effect, he was treated with sorafenib therapy. Two months after the initiation of sorafenib therapy, dynamic computed tomography (CT) showed decreasement of intratumoral enhancement. However, new lesion was pointed out, and modified RECIST showed progressive disease. Intrahepatic new lesion showed decreasement of intratumoral enhancement. Sorafenib therapy was continued at his request. The next 4 months, CT and PIVKA-II plasma levels did not get worse. Six months after the initiation of the therapy, PIVKA-II plasma levels showed marked elevation, and intrahepatic HCC showed intratumoral enhancement. In this case, sorafenib therapy should not be interrupted at 2 months after the initiation of sorafenib therapy.<br>
収録刊行物
-
- 肝臓
-
肝臓 53 (10), 602-609, 2012
一般社団法人 日本肝臓学会
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1390282679769892352
-
- NII論文ID
- 10031120962
-
- NII書誌ID
- AN00047770
-
- ISSN
- 18813593
- 04514203
-
- NDL書誌ID
- 024028335
-
- 本文言語コード
- ja
-
- データソース種別
-
- JaLC
- NDL
- Crossref
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可